^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | OMO-103 (MYC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition
Published date:
10/12/2022
Excerpt:
We used KRAS Lung Adenocarcinoma (KLA) isogenic cell lines….Omomyc significantly reduced in vitro cell growth and changed the cell cycle profile of all KLA cell lines. Even more remarkably, systemic MYC inhibition in C57BL/6x129/Sv mice also displayed therapeutic efficacy in vivo and changed the tumor immune microenvironment in KRAS-mutated tumors.
